RPA Validation in Life Sciences: 5 Pitfalls and How to Avoid Them

The issue with RPA was discovered during an FDA audit at a Global Biotech company. There was a lack of validation documentation, requirement traceability, and testing, and missing evidence. That’s when it was noted that a successful automation project is indeed a regulatory finding. 

This is not an unusual event in life sciences; bots aren’t just scripts, they are regulated systems. The development should include compliance, risk management, and audit readiness, as with any other GxP systems.

This article will take you through five recurring challenges in regulated RPA deployments and offer you practical, developer-focused solutions, from risk-based testing to synthetic data generation. You’ll also see code snippets, diagrams, and validation lessons learned from real-world projects in life sciences.

Why RPA Validation Is Different in Life Sciences

In any industry, such as banking or retail, a failure of an RPA bot might be an inconvenience. But in life sciences, since the RPA bot needs to be submitted to regulatory authorities, a failure can lead to delays in project approvals and/or compromises in patient safety.

This is the reason why agencies like the FDA and EMA expect RPA deployments to follow Computer System Validation (CSV) or the newer Computer Software Assurance (CSA) principles.

It means developers need to develop an audit-ready automation tool for a successful approval, not just a good technical solution.

Challenge #1: Treating RPA Like Standard IT Automation

The Issue

Many teams build bots with the same mindset as IT scripts: design → test → deploy. But as per regulators, bots are not scripts. They are validated systems. Avoiding validation can lead to major audit findings.

The Fix

Adopt a CSV/CSA-based approach:

• Define intended use: Document why the bot exists and its risk assessment.
• Risk-based testing: Test high-risk steps more rigorously (e.g., submissions, data integrity).
• Audit trails: Enable logs that cannot be edited and can be reviewed.

Challenge #2: Breaking the Traceability Chain

The Issue

In regulated projects, every requirement must map to a test case, and every test must trace back to a requirement. If that traceability is broken, then the audits fail.

The Fix

• Maintain a Traceability Matrix (TM) linking requirements → design → bot logic → test case → result.
• Automate TM generation where possible.

Example: Requirement Tagging in Code

# Requirement ID: RPA-REQ-102
# Description: Each Bot action must be recorded in compliance database
def compliance_db(entry):
     timestamp = datetime.now()
     db.insert({"entry": entry, "timestamp": timestamp})

Challenge #3: Skipping Change Control

The Issue

Bots get updated, that includes change in forms, APIs update etc. Without a structured change control, any change to an already validated tool can be invalidated.

The Fix

• Implement bot versioning (Git or enterprise RPA repos).
• Perform impact assessments for each change.
• Use validation by exception: revalidate only impacted areas.

Challenge #4: Testing With Real Production Data

The Issue

RPA bots often touch personal data (e.g., patient records, trial results). Using real production data in validation testing creates compliance and privacy risks.

The Fix

• Use synthetic or masked data in validation.
• Build data factories for realistic, reusable test sets.

Challenge #5: Failing Audit-Readiness Checks

The Issue

During an audit, auditors always want evidence to be presented. Sometimes teams do not have evidence ready, including test results, approvals, and logs.

The Fix

• Automate evidence collection: logs, screenshots, and approvals flow into a validation folder.
• Keep deliverables (URS, FRS, TM, results) audit-ready from Day 1.
• Run mock or Internal audits quarterly.

Case Study: Cutting Audit Prep Time by 40%

A mid-sized biotech company implemented RPA for regulatory submissions but lacked audit preparation. Each inspection required 2–3 weeks of manual evidence gathering. Logs, screenshots, and approvals were scattered across systems.

The solution: They integrated their RPA platform with a centralized evidence collector:

• Execution logs were automatically exported after each run.
• Screenshots were bundled into validation folders.
• Digital approvals flowed into a secure repository.

By implementing this into their RPA lifecycle, the company reduced audit preparation time by 40%. During their next FDA audit, inspectors were given direct, read-only access to the validation repository, which resulted in saving both time and stress.

Lesson for developers: Automating evidence collection isn’t just for compliance; it is also for productivity. Treat it like a CI/CD pipeline for validation artifacts.

Developer Action Plan

Before you start your next RPA build in Life Sciences, ask yourself the following questions:

• Have the bot’s intended use and risks been identified?
• Does each requirement map to code and testing performed via a traceability matrix?
• Is there version control and validation in place?
• Is real data/patient data being used for validation testing, or is it being masked or synthesized? 
• Is the evidence collection continuous and audit-ready?

Final Thoughts

RPA in life sciences isn’t just about reducing costs or manual effort. It is about building bots that are up to regulations, scale globally, and remain resilient as business needs evolve.

By avoiding these challenges, weak validation, broken traceability, poor change control, unsafe test data, and weak audit readiness, you’ll build automation that is efficient, compliant, and audit-ready.

For developers, this isn’t just documentation; it is an opportunity. Validation done right helps you deliver bots that not only work but also endure the toughest audits.